Alliancebernstein L.P. Nkarta, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Nkarta, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 80,690 shares of NKTX stock, worth $200,918. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,690

Previous 80,690 -0.0%

Holding current value

$200,918

Previous $476,000 23.53%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.27 - $10.82 $73,094 - $150,073	13,870 Added 20.76%	80,690 $476,000
Q4 2023 Feb 14, 2024	SELL	$1.31 - $6.6 $5,240 - $26,400	-4,000 Reduced 5.65%	66,820 $441,000
Q2 2023 Aug 15, 2023	BUY	$2.19 - $5.17 $10,555 - $24,919	4,820 Added 7.3%	70,820 $155,000
Q4 2022 Feb 14, 2023	BUY	$5.14 - $14.35 $21,074 - $58,835	4,100 Added 6.62%	66,000 $395,000
Q3 2022 Nov 15, 2022	SELL	$12.27 - $18.39 $58,896 - $88,272	-4,800 Reduced 7.2%	61,900 $815,000
Q2 2022 Aug 15, 2022	BUY	$7.77 - $19.44 $327,894 - $820,368	42,200 Added 172.24%	66,700 $822,000
Q4 2021 Feb 14, 2022	SELL	$12.79 - $26.88 $1.45 Million - $3.04 Million	-112,986 Reduced 82.18%	24,500 $376,000
Q3 2021 Nov 10, 2021	BUY	$26.67 - $38.76 $2.33 Million - $3.39 Million	87,388 Added 174.43%	137,486 $3.82 Million
Q2 2021 Jul 30, 2021	BUY	$23.94 - $36.68 $720,546 - $1.1 Million	30,098 Added 150.49%	50,098 $1.59 Million
Q1 2021 May 06, 2021	SELL	$31.33 - $59.61 $65,793 - $125,181	-2,100 Reduced 9.5%	20,000 $658,000
Q4 2020 Feb 08, 2021	BUY	$27.03 - $75.62 $597,363 - $1.67 Million	22,100 New	22,100 $1.36 Million

Others Institutions Holding NKTX

# of Institutions

127

Shares Held

66.6M

Call Options Held

173K

Put Options Held

20K

View Full List

About Nkarta, Inc.

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $121M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

More about NKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Nkarta, Inc. Transaction History